Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia

Roberto Santangelo, Elisabetta Coppi, Laura Ferrari, Maria Paola Bernasconi, Patrizia Pinto, Gabriella Passerini, Giancarlo Comi, Giuseppe Magnani

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Three variants of primary progressive aphasia (PPA) have been currently characterized: non fluent/agrammatic (nfv-PPA), semantic (sv-PPA), and logopenic variant (lv-PPA). lv-PPA is most commonly associated with Alzheimer's disease (AD), while nfv-PPA and sv-PPA are related to frontotemporal lobar degeneration.

Objective: We aimed to determine whether cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), total tau protein (t-tau), and phosphorylated tau (p-tau), frequently abnormal in AD, could constitute a useful tool in the PPA diagnostic work up, in order to identify subjects with an underlying AD pathology.

Methods: We measured CSF biomarker levels in a group of twenty-eight patients, fourteen lv-PPA, nine nfv-PPA, and five sv-PPA.

Results: Since there were no significant differences in any of the parameters investigated between nfv-PPA and sv-PPA, the two groups were considered as one (nfv/sv-PPA). At diagnosis, lv-PPA were older than nfv/sv-PPA patients (mean values: 70.7 versus 64.6 years, p = 0.02). CSF biomarker mean concentrations were significantly different in lv-PPA versus nfv/sv-PPA patients (p = 0.000): Aβ42 350.64 versus 661.64 ng/L; tau 631.21 versus 232.71 ng/L; p-tau 101 versus 38.21 ng/L. According to the recent AD diagnostic criteria, (Cummings et al., 2013) eleven lv-PPA and only one nfv/sv-PPA showed a liquoral pattern typical for AD. Finally lv-PPA had CSF biomarker levels very similar to a sample of 72 AD patients from our Department.

Conclusions: Our data showed that CSF biomarkers can easily and reliably detect those patients with language disorders due to an underlying AD pathology, thus offering the possibility of targeted therapeutic interventions. However, because of the small sample size, such analyses should be reproduced in larger populations of patients to confirm our data.

Original languageEnglish
Pages (from-to)1429-1440
Number of pages12
JournalJournal of Alzheimer's Disease
Volume43
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Primary Progressive Aphasia
Cerebrospinal Fluid
Biomarkers
Alzheimer Disease
Amyloid

Keywords

  • CSF biomarkers
  • logopenic variant
  • non fluent-agrammatic variant
  • primary progressive aphasia
  • semantic variant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology
  • Medicine(all)

Cite this

Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. / Santangelo, Roberto; Coppi, Elisabetta; Ferrari, Laura; Bernasconi, Maria Paola; Pinto, Patrizia; Passerini, Gabriella; Comi, Giancarlo; Magnani, Giuseppe.

In: Journal of Alzheimer's Disease, Vol. 43, No. 4, 2014, p. 1429-1440.

Research output: Contribution to journalArticle

Santangelo, Roberto ; Coppi, Elisabetta ; Ferrari, Laura ; Bernasconi, Maria Paola ; Pinto, Patrizia ; Passerini, Gabriella ; Comi, Giancarlo ; Magnani, Giuseppe. / Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. In: Journal of Alzheimer's Disease. 2014 ; Vol. 43, No. 4. pp. 1429-1440.
@article{813e5d6e4bc34ff6b50106cfe22d6170,
title = "Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia",
abstract = "Background: Three variants of primary progressive aphasia (PPA) have been currently characterized: non fluent/agrammatic (nfv-PPA), semantic (sv-PPA), and logopenic variant (lv-PPA). lv-PPA is most commonly associated with Alzheimer's disease (AD), while nfv-PPA and sv-PPA are related to frontotemporal lobar degeneration.Objective: We aimed to determine whether cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), total tau protein (t-tau), and phosphorylated tau (p-tau), frequently abnormal in AD, could constitute a useful tool in the PPA diagnostic work up, in order to identify subjects with an underlying AD pathology.Methods: We measured CSF biomarker levels in a group of twenty-eight patients, fourteen lv-PPA, nine nfv-PPA, and five sv-PPA.Results: Since there were no significant differences in any of the parameters investigated between nfv-PPA and sv-PPA, the two groups were considered as one (nfv/sv-PPA). At diagnosis, lv-PPA were older than nfv/sv-PPA patients (mean values: 70.7 versus 64.6 years, p = 0.02). CSF biomarker mean concentrations were significantly different in lv-PPA versus nfv/sv-PPA patients (p = 0.000): Aβ42 350.64 versus 661.64 ng/L; tau 631.21 versus 232.71 ng/L; p-tau 101 versus 38.21 ng/L. According to the recent AD diagnostic criteria, (Cummings et al., 2013) eleven lv-PPA and only one nfv/sv-PPA showed a liquoral pattern typical for AD. Finally lv-PPA had CSF biomarker levels very similar to a sample of 72 AD patients from our Department.Conclusions: Our data showed that CSF biomarkers can easily and reliably detect those patients with language disorders due to an underlying AD pathology, thus offering the possibility of targeted therapeutic interventions. However, because of the small sample size, such analyses should be reproduced in larger populations of patients to confirm our data.",
keywords = "CSF biomarkers, logopenic variant, non fluent-agrammatic variant, primary progressive aphasia, semantic variant",
author = "Roberto Santangelo and Elisabetta Coppi and Laura Ferrari and Bernasconi, {Maria Paola} and Patrizia Pinto and Gabriella Passerini and Giancarlo Comi and Giuseppe Magnani",
year = "2014",
doi = "10.3233/JAD-141122",
language = "English",
volume = "43",
pages = "1429--1440",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia

AU - Santangelo, Roberto

AU - Coppi, Elisabetta

AU - Ferrari, Laura

AU - Bernasconi, Maria Paola

AU - Pinto, Patrizia

AU - Passerini, Gabriella

AU - Comi, Giancarlo

AU - Magnani, Giuseppe

PY - 2014

Y1 - 2014

N2 - Background: Three variants of primary progressive aphasia (PPA) have been currently characterized: non fluent/agrammatic (nfv-PPA), semantic (sv-PPA), and logopenic variant (lv-PPA). lv-PPA is most commonly associated with Alzheimer's disease (AD), while nfv-PPA and sv-PPA are related to frontotemporal lobar degeneration.Objective: We aimed to determine whether cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), total tau protein (t-tau), and phosphorylated tau (p-tau), frequently abnormal in AD, could constitute a useful tool in the PPA diagnostic work up, in order to identify subjects with an underlying AD pathology.Methods: We measured CSF biomarker levels in a group of twenty-eight patients, fourteen lv-PPA, nine nfv-PPA, and five sv-PPA.Results: Since there were no significant differences in any of the parameters investigated between nfv-PPA and sv-PPA, the two groups were considered as one (nfv/sv-PPA). At diagnosis, lv-PPA were older than nfv/sv-PPA patients (mean values: 70.7 versus 64.6 years, p = 0.02). CSF biomarker mean concentrations were significantly different in lv-PPA versus nfv/sv-PPA patients (p = 0.000): Aβ42 350.64 versus 661.64 ng/L; tau 631.21 versus 232.71 ng/L; p-tau 101 versus 38.21 ng/L. According to the recent AD diagnostic criteria, (Cummings et al., 2013) eleven lv-PPA and only one nfv/sv-PPA showed a liquoral pattern typical for AD. Finally lv-PPA had CSF biomarker levels very similar to a sample of 72 AD patients from our Department.Conclusions: Our data showed that CSF biomarkers can easily and reliably detect those patients with language disorders due to an underlying AD pathology, thus offering the possibility of targeted therapeutic interventions. However, because of the small sample size, such analyses should be reproduced in larger populations of patients to confirm our data.

AB - Background: Three variants of primary progressive aphasia (PPA) have been currently characterized: non fluent/agrammatic (nfv-PPA), semantic (sv-PPA), and logopenic variant (lv-PPA). lv-PPA is most commonly associated with Alzheimer's disease (AD), while nfv-PPA and sv-PPA are related to frontotemporal lobar degeneration.Objective: We aimed to determine whether cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), total tau protein (t-tau), and phosphorylated tau (p-tau), frequently abnormal in AD, could constitute a useful tool in the PPA diagnostic work up, in order to identify subjects with an underlying AD pathology.Methods: We measured CSF biomarker levels in a group of twenty-eight patients, fourteen lv-PPA, nine nfv-PPA, and five sv-PPA.Results: Since there were no significant differences in any of the parameters investigated between nfv-PPA and sv-PPA, the two groups were considered as one (nfv/sv-PPA). At diagnosis, lv-PPA were older than nfv/sv-PPA patients (mean values: 70.7 versus 64.6 years, p = 0.02). CSF biomarker mean concentrations were significantly different in lv-PPA versus nfv/sv-PPA patients (p = 0.000): Aβ42 350.64 versus 661.64 ng/L; tau 631.21 versus 232.71 ng/L; p-tau 101 versus 38.21 ng/L. According to the recent AD diagnostic criteria, (Cummings et al., 2013) eleven lv-PPA and only one nfv/sv-PPA showed a liquoral pattern typical for AD. Finally lv-PPA had CSF biomarker levels very similar to a sample of 72 AD patients from our Department.Conclusions: Our data showed that CSF biomarkers can easily and reliably detect those patients with language disorders due to an underlying AD pathology, thus offering the possibility of targeted therapeutic interventions. However, because of the small sample size, such analyses should be reproduced in larger populations of patients to confirm our data.

KW - CSF biomarkers

KW - logopenic variant

KW - non fluent-agrammatic variant

KW - primary progressive aphasia

KW - semantic variant

UR - http://www.scopus.com/inward/record.url?scp=84919915325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919915325&partnerID=8YFLogxK

U2 - 10.3233/JAD-141122

DO - 10.3233/JAD-141122

M3 - Article

C2 - 25201781

AN - SCOPUS:84919915325

VL - 43

SP - 1429

EP - 1440

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -